Clinical Trials Directory

Trials / Completed

CompletedNCT06663527

Compound Phellodendron Decoction May Promote Wound Healing After Anal Fistulotomy

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Sitz-bath therapy with Chinese medicine has significant advantages in the management of postoperative wounds of anal fistula. This method not only ensures safety, efficacy, and cost-effectiveness, but also simplifies application. With a firm foundation in a historical heritage, this method is notable for their minimal adverse reactions. The fumigating-washing or sitz-bath therapy with Compound Phellodendron Decoction (CPD) for postoperative wounds of anal fistula has demonstrated efficacy in mitigating pain, reducing edema, curbing secretions, alleviating skin itching, and promoting wound healing processes. Despite the body of clinical research in this domain is substantial, the majority of studies have been limited to observing therapeutic outcomes. The intrinsic mechanisms by which these effects are achieved remain elusive. This study aims to unravel the potential mechanisms underpinning CPD's promotion of wound healing, focusing on the aspects of inflammation and immunity.

Conditions

Interventions

TypeNameDescription
COMBINATION_PRODUCTFumigating-washing Therapy With CPDAll patients underwent anal fistulectomy based on the Parks classification. For postoperative infection prophylaxis, cefuroxime was used at a dosage of 2g per dose, twice daily. Commencing the day following surgery, a fumigating-washing therapy was conducted once daily either after defecation or two hours prior to intravenous infusion. In the study group, a medical solution used for fumigating-washing therapy was prepared by blending 200 ml of CPD with 2 liters of water at 40 °C. This medicinal solution was then transferred into the reservoir of an ultrasonic atomizing fumigating-washing device (Model:TM50-C, Xuzhou Tianma Medical Equipment Factory, China) that was classified by the FDA as Class II (special controls).
COMBINATION_PRODUCTfumigating-washing therapy with a placebofumigating-washing therapy with a placebo

Timeline

Start date
2024-10-26
Primary completion
2025-02-01
Completion
2025-02-01
First posted
2024-10-29
Last updated
2025-08-12

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06663527. Inclusion in this directory is not an endorsement.